Suppr超能文献

C反应蛋白与白蛋白比值在胃癌中的预后价值:一项Meta分析

Prognostic Value of C-Reactive Protein to Albumin Ratio in Gastric Cancer: A Meta-Analysis.

作者信息

Yue Liang, Lu Yi, Li Yulin, Wang Yilin

机构信息

Faculty of Medicine and Life Sciences, Chengdu University of Traditional Chinese Medicine, Chengdu, China.

Department of Thoracic Surgery, Chongqing University Three Gorges Hospital & Chongqing Three Gorges Central Hospital, Chongqing, China.

出版信息

Nutr Cancer. 2021;73(10):1864-1871. doi: 10.1080/01635581.2020.1817510. Epub 2020 Sep 17.

Abstract

OBJECTIVE

C-reactive protein to albumin ratio (CRP/Alb) is investigated as a prognostic marker in gastric cancer in previous studies, with presence of inconsistent data. Therefore, this study aimed to explore the prognostic role of CRP/Alb in gastric cancer through meta-analysis.

METHODS

This meta-analysis systemically retrieved PubMed, Embase, Web of Science, the Chinese National Knowledge Infrastructure (CNKI), and Wanfang up to July 4, 2020. Pooled hazard ratios (HRs) and corresponding 95% confidence intervals (CIs) were conducted to evaluate the association between CRP/Alb and survival outcomes.

RESULTS

A total of nine studies with 3346 patients were included in the present meta-analysis. The pooled HR and 95%CI were: HR = 1.89, 95%CI = 1.64-2.19,  < 0.001 for overall survival (OS) and HR = 2.15, 95%CI = 1.72-2.70,  < 0.001 for disease-free survival (DFS). Subgroup analysis demonstrate that an elevated CRP/Alb remain a significant prognostic factor for poor OS and DFS irrespective of sample size, nationality of patients, or cutoff value resource ( < 0.05 in all subgroups).

CONCLUSIONS

The present meta-analysis suggests that high CRP/Alb is predictive of poor OS and DFS in gastric cancer. CRP/Alb is therefore a potential prognostic factor in the management of patients with gastric cancer.

摘要

目的

在先前的研究中,C反应蛋白与白蛋白比值(CRP/Alb)被作为胃癌的一种预后标志物进行研究,但数据存在不一致性。因此,本研究旨在通过荟萃分析探讨CRP/Alb在胃癌中的预后作用。

方法

本荟萃分析系统检索了截至2020年7月4日的PubMed、Embase、Web of Science、中国知网(CNKI)和万方数据库。采用合并风险比(HRs)及相应的95%置信区间(CIs)来评估CRP/Alb与生存结局之间的关联。

结果

本荟萃分析共纳入9项研究,涉及3346例患者。总体生存(OS)的合并HR及95%CI为:HR = 1.89,95%CI = 1.64 - 2.19,P < 0.001;无病生存(DFS)的合并HR及95%CI为:HR = 2.15,95%CI = 1.72 - 2.70,P < 0.001。亚组分析表明,无论样本量、患者国籍或截断值来源如何,CRP/Alb升高仍是OS和DFS不良的显著预后因素(所有亚组P < 0.05)。

结论

本荟萃分析表明,高CRP/Alb预示着胃癌患者的OS和DFS较差。因此,CRP/Alb是胃癌患者管理中的一个潜在预后因素。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验